Related Experiment Video
Updated: May 10, 2026
10:56
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Familial hypercholesterolaemia: new treatment options
M Ezzahti1, E J G Sijbrands, M T Mulder
1Department of Vascular Medicine, Erasmus MC, Rotterdam, The Netherlands. m.ezzahti@erasmusmc.nl
The Netherlands Journal of Medicine
|June 27, 2013
Summary
New cholesterol-lowering drugs show promise for treating familial hypercholesterolaemia (FH). These agents offer potential improvements in lipid reduction and safety, addressing variable responses to current therapies in FH patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Familial hypercholesterolaemia (FH) is a common genetic disorder.
- FH significantly increases the risk of premature vascular disease.
- Current lipid-lowering treatments for FH demonstrate variable efficacy.
Purpose of the Study:
- To review emerging cholesterol-lowering drugs for familial hypercholesterolaemia.
- To evaluate the lipid-lowering potential and safety of new FH agents.
- To explore the potential of these drugs in reducing residual cardiovascular risk in FH patients.
Main Methods:
- Review of phase 2 and phase 3 clinical trial data for novel cholesterol-lowering agents.
- Analysis of lipid profiles and safety data from available studies.
- Discussion of clinical implications for managing familial hypercholesterolaemia.
Main Results:
- Several new agents demonstrate significant lipid-lowering effects in FH patients.
- Safety profiles of these novel drugs are being evaluated.
- Potential for improved management of hypercholesterolaemia and reduced cardiovascular risk.
Conclusions:
- New pharmacological options are emerging for familial hypercholesterolaemia treatment.
- These agents may offer enhanced efficacy and improved safety over existing therapies.
- Further research is needed to establish their long-term impact on residual cardiovascular risk.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...